Sumitomo Pharma Co

Sumitomo Pharma Co EBIT

The EBIT of Sumitomo Pharma Co (4506.T) as of Nov 4, 2026 is 50.34 B JPY. In the previous year, EBIT was 22.42 B JPY — a change of 124.51% (higher).

EBIT

50.34 BJPY

YoY

124.51%

Last updated:

In 2026, Sumitomo Pharma Co's EBIT was 50.34 B JPY, a 124.51% increase from the 22.42 B JPY EBIT recorded in the previous year.

The Sumitomo Pharma Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2024
-1.48 B JPY
Jan 1, 2025
22.42 B JPY
Jan 1, 2026
50.34 B JPY
Jan 1, 2027 (e)
102.58 B JPY
Jan 1, 2028 (e)
104.64 B JPY
Jan 1, 2029 (e)
85.27 B JPY
Jan 1, 2030 (e)
72.19 B JPY
Jan 1, 2031 (e)
40.07 B JPY
The Sumitomo Pharma Co EBIT history
YEAREBITYoY
est40.07 BJPY-44.50%
est72.19 BJPY-15.35%
est85.27 BJPY-18.51%
est104.64 BJPY+2.01%
est102.58 BJPY+103.77%
50.34 BJPY+124.51%
22.42 BJPY-1,620.14%
-1.48 BJPY-113.17%
11.20 BJPY-80.19%
56.55 BJPY-17.30%
68.38 BJPY+33.86%
51.08 BJPY-10.70%
57.21 BJPY-28.17%
79.64 BJPY+30.62%
60.97 BJPY+65.11%
36.93 BJPY+58.66%
23.28 BJPY-44.77%
42.14 BJPY+68.28%
25.04 BJPY+22.75%
20.40 BJPY-34.50%
31.15 BJPY-13.14%
35.86 BJPY+15.05%
31.17 BJPY-21.72%
39.81 BJPY-12.60%
45.55 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sumitomo Pharma Co Revenue

Sumitomo Pharma Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
314.56 B JPY
-1.48 B JPY
-314.97 B JPY
Jan 1, 2025
398.83 B JPY
22.42 B JPY
23.63 B JPY
Jan 1, 2026
453.29 B JPY
50.34 B JPY
106.87 B JPY
Jan 1, 2027 (e)
566.97 B JPY
102.58 B JPY
87.53 B JPY
Jan 1, 2028 (e)
617.25 B JPY
104.64 B JPY
87.79 B JPY
Jan 1, 2029 (e)
618.33 B JPY
85.27 B JPY
68.59 B JPY
Jan 1, 2030 (e)
594.63 B JPY
72.19 B JPY
60.06 B JPY
Jan 1, 2031 (e)
629.12 B JPY
40.07 B JPY
30.15 B JPY

Sumitomo Pharma Co Margins

Sumitomo Pharma Co stock margins

The Sumitomo Pharma Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sumitomo Pharma Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sumitomo Pharma Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
49.94 %
-0.47 %
-100.13 %
Jan 1, 2025
56.51 %
5.62 %
5.93 %
Jan 1, 2026
56.67 %
11.11 %
23.58 %
Jan 1, 2027 (e)
56.67 %
18.09 %
15.44 %
Jan 1, 2028 (e)
56.67 %
16.95 %
14.22 %
Jan 1, 2029 (e)
56.67 %
13.79 %
11.09 %
Jan 1, 2030 (e)
56.67 %
12.14 %
10.10 %
Jan 1, 2031 (e)
56.67 %
6.37 %
4.79 %

Sumitomo Pharma Co Stock analysis

What does Sumitomo Pharma Co do? Sumitomo Dainippon Pharma Co Ltd is a biopharmaceutical company headquartered in Osaka, Japan. It was originally founded as Dainippon Pharmaceutical Co. Ltd in 1885 and later merged with Sumitomo Pharmaceuticals in 2005 to form the new Sumitomo Dainippon Pharma. The company operates in various areas, such as psychiatric and neurological medicine, oncology, dermatology, and infectious diseases. The products include both prescription and over-the-counter medications. In psychiatric and neurological medicine, Sumitomo Dainippon Pharma offers drugs that can be used to treat depression, anxiety disorders, schizophrenia, and bipolar disorders. One of the most well-known medications in this category is the antipsychotic Latuda, which is used for schizophrenia and bipolar disorder. In oncology, Sumitomo Dainippon Pharma has developed medications that can be used in the treatment of cancers such as lung, liver, pancreatic, colorectal, and blood cancer. The company is also involved in developing treatments for rare forms of cancer and immune-mediated diseases. In dermatology, Sumitomo Dainippon Pharma has developed medications for the treatment of skin and nail infections, psoriasis, and atopic dermatitis. The company is also working on innovative treatment approaches for skin cancer and other types of skin diseases. Sumitomo Dainippon Pharma is also involved in the development of treatments for infectious diseases, including medications for HIV and hepatitis C. The business model of Sumitomo Dainippon Pharma is based on the development of new drugs and the marketing of prescription and over-the-counter medications on a global level. The company focuses on researching and developing drugs that can address significant medical needs and that differentiate themselves from other medications on the market. The products are registered and marketed in various countries, especially in the US and Japan. Sumitomo Dainippon Pharma invests significantly in research and development. The company has R&D sites in Japan, the US, UK, and Ireland. It also collaborates with other companies to leverage innovative technologies and accelerate the development of new medications. Overall, Sumitomo Dainippon Pharma has a long history in the pharmaceutical industry and is committed to creating a wide range of medications and therapies for various diseases and conditions. The company is dedicated to improving the lives of patients and contributing to the well-being of society as a whole. Sumitomo Pharma Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Sumitomo Pharma Co's EBIT

Sumitomo Pharma Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Sumitomo Pharma Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Sumitomo Pharma Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Sumitomo Pharma Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Sumitomo Pharma Co stock

EBIT of Sumitomo Pharma Co is 50.34 B JPY in 2026.

EBIT of Sumitomo Pharma Co changed from 22.42 B JPY to 50.34 B JPY, representing a 124.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Sumitomo Pharma Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Sumitomo Pharma Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Sumitomo Pharma Co

All Key Metrics — Sumitomo Pharma Co